1naresh

Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1nareshArray
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)

Table 3: Longitudinal SPECT studies on at-risk subjects
Study N Decline Baseline Clinical Characteristics^* FU Tracer
Age (yr) M MMSE Ed
Borroni et al, 2006¹⁶ 27/18 MCI to AD 69.4 (7.1) 22.2 27.5 (1.9) NA 24 ECD 1110 MBq
Ishiwata et al, 2006¹⁷ 12/7 AAMI to D 74 33.3 NA NA 36 IMP 222 MBq
Johnson et al, 1998¹⁸ 45/18 QA to AD 72.5 NA NA 14.8 ≥24 HMPAO 20 mCi
Encinas et al, 2003¹⁹ 42/21 MCI to AD 76.5 (4.2) 35.7 NA NA 12–36 ECD 750 MBq
O'Mahony et al, 1994²⁰ 15/11 MCI to AD 72.6 33.3 23.3 NA 6 HMPAO 740 MBq
Hirao et al, 2005²¹ 76/52 aMCI to AD 69.0 (8.6) 48.7 26.5 (1.6) 12.2 (2.9) 36 ECD 600 MBq
Huang et al, 2003²² 82/28 MCI to D 60.9 (9.2) 45.1 NA NA 26.4 HMPAO 1000 MBq
Huang et al, 2002²³ 54/17 MCI to AD 61.3 (8.2) 38.9 26.7 (2.2) NA 28.9 HMPAO 1000 MBq
Note:—ECD indicates ethyl cysteinate dimer; IMP, iodoamphetamine; HMPAO, hexamethyl propyleneamine oxime; QA, questionable AD; SPECT, single-photon emission tomography.
* Each cell was listed as mean value (SD).